Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?

Azadeh Moghaddas; Ali Borhani

Volume 5, Issue 4 , October 2016, , Pages 227-233

Abstract
  The National Comprehensive Cancer Network (NCCN) has recommended Ado-trastuzumab emtansine (T-DM1) as a preferred agent for patients with human epidermal growth factor receptor-2 (HER2)-positive ...  Read More